Pharma Stocks
-
Ascendis Pharma (NasdaqGS:ASND): Valuation Insights After TransCon CNP Application Advances European Approval Journey
Ascendis Pharma (NasdaqGS:ASND) just took a major step forward by submitting a Marketing Authorisation Application to the European Medicines Agency…
Read More » -
aTyr Pharma (ATYR) Faces Legal Scrutiny After Failed Efzofitimod Trial – Can Its Credibility Recover?
aTyr Pharma recently reported that its Phase 3 trial for efzofitimod in pulmonary sarcoidosis failed to meet its primary endpoint,…
Read More » -
Jazz Pharmaceuticals (JAZZ): Assessing Valuation Following Recent Net Income Growth and Share Price Recovery
Jazz Pharmaceuticals (JAZZ) has delivered an annual net income growth of over 54% due to steady revenue increases, drawing renewed…
Read More » -
New to The Street Broadcasts Tonight on Bloomberg Featuring Roadzen, Metaterra, NRx Pharma, Blackbarn NYC, and Humanitarian Travel Group
The show is sponsored programming with commercials featuring LASE Technologies ($LASE), PetVivo ($PETV), Acurx Pharmaceuticals ($ACXP), Synergy CHC ($SNYR), and…
Read More » -
Does ILMN’s BioInsight Launch Signal a New Chapter in Data-Driven Drug Discovery Strategy?
In early October 2025, Illumina announced the launch of BioInsight, a new business unit led by Rami Mehio focused on…
Read More » -
aTyr Pharma (ATYR): Evaluating Valuation Following New Efzofitimod Data and Securities Lawsuit
aTyr Pharma (ATYR) is drawing attention after presenting fresh Phase 3 results for its lead drug candidate, efzofitimod, at a…
Read More » -
IGC Pharma Announces Increase to 600M Authorized Shares
IGC Pharma (NYSE American: IGC) held its Annual Meeting on October 10,…
Read More » -
Ascendis Pharma (ASND) Is Up 6.9% After EMA Filing for TransCon CNP in Achondroplasia Treatment
On October 8, 2025, Ascendis Pharma A/S announced it had submitted a Marketing Authorisation Application to the European Medicines Agency…
Read More » -
What If You Were Missing The Value In Regeneron Pharmaceuticals Stock?
Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images SOPA Images/LightRocket via Getty Images Here’s why we believe Regeneron Pharmaceuticals…
Read More » -
A Look at Ionis Pharmaceuticals’s Valuation Following Pipeline Progress and Strong Innovation Day Updates
Ionis Pharmaceuticals (IONS) jumped to a six-year high after its 2025 Innovation Day, where management shared upbeat Phase 3 results…
Read More »